Some systemic and biologic psoriasis treatments [SBT] have been associated with an increased risk of infection.(1) To date, more and more data regarding the risk of COVID‐19 infection in patients receiving SBT becomes available.(2‐5) To enrich these data, we evaluated the frequency of severe COVID‐19 infections, defined as hospitalisation or death, in psoriasis patients receiving SBT, especially during the 4 months following SBT initiation.